GlassScriptPhysician profile
Kurtis Opp
NPI 1275627796
$19,112.82
in general payments reported to CMS, 2019-2025
36 companies · $4,906 in 2025
The $4,906 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,494 · 2022: $2,724 · 2023: $3,900 · 2024: $5,088 · 2025: $4,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,064 · Education: $99.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,730.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,064.00 |
| Education | $99.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,995.28 | 2021-2025 | |
| Genzyme Corporation | $2,500.94 | 2021-2025 | |
| Leo Pharma INC. | $1,746.21 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Lilly USA, LLC | $1,494.64 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $988.87 | 2021-2025 | |
| Incyte Corporation | $983.86 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $916.62 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $788.27 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $758.34 | 2021-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $719.89 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $644.47 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $576.87 | 2021-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $514.01 | 2023-2025 | Sotyktu |
| Ucb, INC. | $503.94 | 2021-2025 | Bimzelx |
| Amgen INC. | $439.41 | 2021-2024 | Otezla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $353.30 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.33 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $232.33 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Organon LLC | $225.32 | 2025 | Vtama |
| Vertex Pharmaceuticals Incorporated | $221.82 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.64 | 2023 | Lifevest |
| Madrigal Pharmaceuticals | $129.87 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $122.39 | 2025 | Apretude |
| Glaxosmithkline, LLC. | $118.74 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $114.27 | 2023 | Relyvrio |
| Gilead Sciences, INC. | $108.39 | 2023 | Epclusa |
| Eisai INC. | $105.90 | 2023 | |
| Biogen, INC. | $81.97 | 2022 | |
| Vyne Pharmaceuticals INC. | $78.18 | 2021 | |
| Almirall LLC | $70.77 | 2021-2024 | Klisyri |
| Neurocrine Biosciences, INC. | $62.63 | 2024 | Ingrezza |
| Journey Medical Corporation | $38.20 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $30.26 | 2021 | |
| Epi Health, LLC | $24.78 | 2021 | |
| Allergan, INC. | $20.54 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurtis Opp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.